Clinical Trial Update: Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for tanespimycin in women with refractory locally advanced or metastatic breast cancer; the trial was terminated and results were …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• tanespimycin (17-N-allylamino-17-demethoxygeldanamycin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Breast Cancer, Stage IIIB Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-01-16